- Home
- GDYN vs RIGL Comparison
GDYN vs RIGL Comparison
Compare GDYN & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDYN | RIGL |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 509.3M | 564.7M |
| IPO Year | 2018 | 2000 |
Fundamental Metrics
Financial Performance| Metric | GDYN | RIGL |
|---|---|---|
| Price | $5.78 | $40.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $10.67 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 2.6M | 386.8K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 120.00 | ★ 1867.68 |
| EPS | N/A | ★ 0.44 |
| Revenue | $111,283,000.00 | ★ $294,282,000.00 |
| Revenue This Year | $10.16 | N/A |
| Revenue Next Year | $10.84 | $12.75 |
| P/E Ratio | ★ N/A | $94.93 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $5.11 | $18.81 |
| 52 Week High | $10.86 | $52.24 |
Technical Indicators
Market Signals| Indicator | GDYN | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | 62.42 |
| Support Level | $5.29 | $40.05 |
| Resistance Level | $6.11 | $44.42 |
| Average True Range (ATR) | 0.36 | 1.90 |
| MACD | 0.03 | -0.23 |
| Stochastic Oscillator | 35.15 | 45.33 |
Price Performance
Historical ComparisonAbout GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.